• All
  • Financials
  • Insiders
Webull provides the latest Corbus Pharms (CRBP) stock and general news. This information may help you make smarter investment decisions.
About CRBP
Corbus Pharmaceuticals Holdings, Inc. is a Phase-III, clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. It develops a diverse pipeline of drug candidates across programs, including small molecules as well as biologics. The Company's lead product candidate, Lenabasum, a novel, synthetic, oral, cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation, limit fibrosis and support tissue repair. Lenabasum is in clinical development for treatment of autoimmune diseases. It is evaluating lenabasum and is in a Phase III study in dermatomyositis, as well as a Phase II study in systemic lupus erythematosus (SLE). It designs cannabinoid receptor type 1 (CB1) inverse agonists to normalize metabolic abnormalities or limit inflammation and fibrosis.